Prevalence of and risk factors for lipodystrophy among HIVinfected patients receiving combined antiretroviral treatment in the Asia-pacific region: Results from the TREAT asia HIV observational database (TAHOD)

Endocrine Journal

Volumn 58, Issue 6, 2011, Pages 475-484

  Han, Sang Hoon ^a   Zhou, Jialun ^b   Saghayam, Suneeta ^c   Vanar, Sasheela ^d   Phanuphak, Nittaya ^e   Chen, Yi Ming A ^f   Sirisanthana, Thira ^g   Sungkanuparph, Somnuek ^h   Lee, Christopher K C ⁱ   Pujari, Sanjay ^j   Li, Patrick C K ^k   Oka, Shinichi ^l   Saphonn, Vonthanak ^m   Zhang, Fujie ⁿ   Merati, Tuti Parwati ^o   Law, Matthew G ^b   Choi, Jun Yong ^a  

^a Yonsei University College of Medicine   (South Korea)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c YRG CENTRE FOR AIDS RESEARCH AND EDUCATION   (India)

^d UNIVERSITY OF MALAYA   (Malaysia)

^e THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^f NATIONAL YANG MING UNIVERSITY   (Taiwan)

^g Research Institute for Health Sciences   (Thailand)

^h MAHIDOL UNIVERSITY   (Thailand)

ⁱ HOSPITAL SUNGAI BULOH   (Malaysia)

^j Institute of Infectious Diseases   (India)

^k QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^l NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^m National Center for HIV/AIDS   (Cambodia)

ⁿ CAPITAL MEDICAL UNIVERSITY   (China)

^o UDAYANA UNIVERSITY   (Indonesia)

more..

Author keywords

Adverse effects; Asia pacific; Combined antiretroviral treatment; HIV; Lipodystrophy

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; INDINAVIR; LOPINAVIR; NELFINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASIA; ASIAN CONTINENTAL ANCESTRY GROUP; COHORT STUDIES; DATABASES, FACTUAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; PREVALENCE; RISK FACTORS; STAVUDINE;

EID: 79959944286     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K10E-407     Document Type: Article

References (33)

1. Carr A, Cooper DA (1998) Images in clinical medicine. Lipodystrophy associated with an HIV-protease inhibitor. N Engl J Med 339: 1296.
2. Grinspoon S, Carr A (2005) Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 352: 48-62.
3. Spire B, Carrieri P, Sopha P, Protopopescu C, Prak N, Quillet C, Ngeth C, Ferradini L, Delfraissy JF, Laureillard D (2008) Adherence to antiretroviral therapy in patients enrolled in a comprehensive care program in Cambodia: a 24-month follow-up assessment. Antivir Ther 13: 697-703.
4. Fernandes AP, Sanches RS, Mill J, Lucy D, Palha PF, Dalri MC (2007) Lipodystrophy syndrome associated with antiretroviral therapy in HIV patients: considerations for psychosocial aspects. Rev Lat Am Enfermagem 15: 1041-1045.
5. Zhou J, Paton NI, Ditangco R, Chen YM, Kamarulzaman A, Kumarasamy N, Lee CK, Li PC, Merati TP, Phanuphak P, Pujari S, Vibhagool A, Zhang F, Chuah J, Frost KR, Cooper DA, Law MG (2007) Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV Observational Database. HIV Med 8: 8-16.
6. Wohl DA, Brown TT (2008) Management of morphologic changes associated with antiretroviral use in HIV-infected patients. J Acquir Immune Defic Syndr 49 Suppl 2: S93-S100.
7. Asensi V, Rego C, Montes AH, Collazos J, Carton JA, Castro MG, Alvarez V, Fernandez C, Maradona JA, Valle-Garay E (2008) IL-1beta (+3954C/T) polymorphism could protect human immunodeficiency virus (HIV)-infected patients on highly active antiretroviral treatment (HAART) against lipodystrophic syndrome. Genet Med 10: 215-223.
8. Bonnet E, Bernard J, Fauvel J, Massip P, Ruidavets JB, Perret B (2008) Association of APOC3 polymorphisms with both dyslipidemia and lipoatrophy in HAARTreceiving patients. AIDS Res Hum Retroviruses 24: 169-171.
9. Guallar JP, Gallego-Escuredo JM, Domingo JC, Alegre M, Fontdevila J, Martinez E, Hammond EL, Domingo P, Giralt M, Villarroya F (2008) Differential gene expression indicates that 'buffalo hump' is a distinct adipose tissue disturbance in HIV-1-associated lipodystrophy. AIDS 22: 575-584.
10. UNAIDS/WHO: 2008 Report on the global HIV/AIDS epidemic. The Joint United Nations Programme on HIV/AIDS page. Available at: http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/2008_Global_report.asp Geneva Switzerland 2008.
11. Chuapai Y, Kiertiburanakul S, Malathum K, Sungkanuparph S (2007) Lipodystrophy and dyslipidemia in human immunodeficiency virus-infected Thai patients receiving antiretroviral therapy. J Med Assoc Thai 90: 452-458.
12. Puttawong S, Prasithsirikul W, Vadcharavivad S (2004) Prevalence of lipodystrophy in Thai-HIV infected patients. J Med Assoc Thai 87: 605-611.
13. Paton NI, Earnest A, Ng YM, Karim F, Aboulhab J (2002) Lipodystrophy in a cohort of human immunodeficiency virus-infected Asian patients: prevalence, associated factors, and psychological impact. Clin Infect Dis 35: 1244-1249.
14. Chang KH, Kim JM, Song YG, Hong SK, Lee HC, Lim SK (2002) Does race protect an oriental population from developing lipodystrophy in HIV-infected individuals on HAART? J Infect 44: 33-38.
15. Zhou J, Kumarasamy N, Ditangco R, Kamarulzaman A, Lee CK, Li PC, Paton NI, Phanuphak P, Pujari S, Vibhagool A, Wong WW, Zhang F, Chuah J, Frost KR, Cooper DA, Law MG (2005) The TREAT Asia HIV Observational Database: baseline and retrospective data. J Acquir Immune Defic Syndr 38: 174-179.
16. Centers for Disease Control and Prevention (1992) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm. Rep., 41, 1-19.
17. The World Bank Group: Country Classification. 2006 Available at: http://web.worldbank.org/WBSITE/EXTERNAL/DATASTATISTICS/0,contentMDK:20420458~menuPK:64133156~pagePK:64133150~piPK:64133175~theSitePK:239419,00.html.
18. US National Institutes of Health DAIDS HIV Vaccines and Research Program. National Institutes of Health. Division of AIDS (DAIDS) revised toxicity tables for grading the severity of adult and pediatric adverse events experiences, Version 1.0, December 2004, Washington. DC. Available at http://rsc.tech- res.com/Document/safetyandpharmacovigilance/Table_for_Grading_Severity_of_Adult_Pediatric_Adverse_Events.doc.
19. Chen D, Misra A, Garg A (2002) Clinical review 153: Lipodystrophy in human immunodeficiency virusinfected patients. J Clin Endocrinol Metab 87: 4845-4856.
20. Bernasconi E, Boubaker K, Junghans C, Flepp M, Furrer HJ, Haensel A, Hirschel B, Boggian K, Chave JP, Opravil M, Weber R, Rickenbach M, Telenti A (2002) Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 31: 50-55.
21. Miller J, Carr A, Emery S, Law M, Mallal S, Baker D, Smith D, Kaldor J, Cooper DA (2003) HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med 4: 293-301.
22. Lichtenstein KA, Ward DJ, Moorman AC, Delaney KM, Young B, Palella FJ, Jr., Rhodes PH, Wood KC, Holmberg SD (2001) Clinical assessment of HIVassociated lipodystrophy in an ambulatory population. Aids 15: 1389-1398.
23. Pere D, Ignacio SL, Ramon T, Fernando L, Alberto T, Pompeyo V, Juan G, G MJ, Paloma G, Antonio V, Jaime C, Esteban R, Bernardino R, GA ML, Trinitario S, Ferran T, Juan Ramon L, Myriam G (2008) Dyslipidemia and Cardiovascular Disease Risk Factor Management in HIV-1-Infected Subjects Treated with HAART in the Spanish VACH Cohort. Open AIDS J 2: 26-38.
24. Nguyen A, Calmy A, Schiffer V, Bernasconi E, Battegay M, Opravil M, Evison JM, Tarr PE, Schmid P, Perneger T, Hirschel B (2008) Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006. HIV Med 9: 142-150.
25. Mallal SA, John M, Moore CB, James IR, McKinnon EJ (2000) Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. Aids 14: 1309-1316.
26. Lichtenstein KA (2005) Redefining lipodystrophy syndrome: risks and impact on clinical decision making. J Acquir Immune Defic Syndr 39: 395-400.
27. Haubrich RH, Riddler SA, DiRienzo AG, Komarow L, Powderly WG, Klingman K, Garren KW, Butcher DL, Rooney JF, Haas DW, Mellors JW, Havlir DV (2009) Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. Aids 23: 1109-1118.
28. Haugaard SB (2006) Toxic metabolic syndrome associated with HAART. Expert Opin Drug Metab Toxicol 2: 429-445.
29. Perez-Molina JA, Domingo P, Martinez E, Moreno S (2008) The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy. J Antimicrob Chemother 62: 234-245.
30. Dube MP, Komarow L, Mulligan K, Grinspoon SK, Parker RA, Robbins GK, Roubenoff R, Tebas P (2007) Long-term body fat outcomes in antiretroviral-naïve participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384. J Acquir Immune Defic Syndr 45: 508-514.
31. Jemsek JG, Arathoon E, Arlotti M, Perez C, Sosa N, Pokrovskiy V, Thiry A, Soccodato M, Noor MA, Giordano M (2006) Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients. Clin Infect Dis 42: 273-280.
32. Cameron DW, da Silva BA, Arribas JR, Myers RA, Bellos NC, Gilmore N, King MS, Bernstein BM, Brun SC, Hanna GJ (2008) A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J Infect Dis 198: 234-240.
33. Srasuebkul P, Calmy A, Zhou J, Kumarasamy N, Law M, Lim PL (2007) Impact of drug classes and treatment availability on the rate of antiretroviral treatment change in the TREAT Asia HIV Observational Database (TAHOD). AIDS Res Ther 4: 18.